Prognostic Significance of Left Ventricular Hypertrophy Regression

  • Enrico Agabiti-RoseiEmail author
  • Maria Lorenza Muiesan
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 432)


In hypertension, left ventricular hypertrophy (LVH) is initially a useful compensatory process, that represents an adaptation to increased ventricular wall stress; however, it is also the first step toward the development of overt clinical disease, such as congestive heart failure, cardiac dysrrhythmias, and ischemic heart disease. In fact, the Framingham Study has shown that once LVH is recognized clinically it constitutes a powerful independent risk factor for future cardiovascular morbid events whether assessed by ECG or echocardiography, the latter being a specific, repeatable and far more sensitive measure of LVH1,2. The echocardiographic technique has demonstrated that the geometric adaptation of the left ventricle to increased cardiac load may be different among patients. Concentric hypertrophy is characterized by increased mass and increased relative wall thickness, whereas eccentric hypertrophy is characterized by increased mass and relative wall thickness < 0.45; on the other hand, concentric remodeling occurs when there is increased thickness with respect to radius, without increased LV mass. Concentric hypertrophy appears to carry the highest risk and eccentric hypertrophy an intermediate risk, whereas concentric remodeling is probably associated with a smaller, albeit still consistent risk3.


Leave Ventricular Hypertrophy Left Ventricular Mass Relative Wall Thickness Concentric Hypertrophy Eccentric Hypertrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kannel WB, Gordon T, Offut T. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham study. Ann. Int. Med., 71: 89 (1969).PubMedGoogle Scholar
  2. 2.
    Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J Med, 322: 1561–1566 (1990).PubMedCrossRefGoogle Scholar
  3. 3.
    Koren MJ Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med, 114: 345–352 (1991).PubMedGoogle Scholar
  4. 4.
    Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Pressure, 1: 201–211 (1992).CrossRefGoogle Scholar
  5. 5.
    Sen S, Tarazi RC. Reversal of myocardial hypertrophy and influence of the adrenergic system. Am J Physiol, 244: H97–H101 (1983).PubMedGoogle Scholar
  6. 6.
    Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. lack of association to blood pressure control. Am J Cardiol, 49: 759–801 (1982).Google Scholar
  7. 7.
    Drayer JIM, Gardin JM, Weber MA, Aronow WS. Cadiac muscle mass during vasodilation therapy in hypertension. Clin Pharmacol Ther, 33: 727–732 (1983).PubMedCrossRefGoogle Scholar
  8. 8.
    Agabiti-Rosei E, Muiesan ML, Romanelli G, et al. Reversal of cardiac hypertrophy by long term treatment with calcium antagonists in hypertensive patients. J Cardiovasc Pharmacol, 12(suppl 6): 75–77 (1988).CrossRefGoogle Scholar
  9. 9.
    Dahlöf B, Pennert K, Hansson L. Reversal of Left Ventricular Hypertrophy in Hypertensive Patients. A Metaanalysis of 109 Treatment Studies. Am J Hypertens, 5: 95–110 (1992).PubMedGoogle Scholar
  10. 10.
    Cruickshank J.M., Lewis J, Moore V, Dodd A. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Human Hypertens, 6: 85–90 (1992).Google Scholar
  11. 11.
    Agabiti-Rosei E, Muiesan ML, Castellano M. Methodology of studies on reversal of left ventricular hypertrophy. High Blood Press, 2(suppl 1): 11–13 (1993).Google Scholar
  12. 12.
    Schmieder AM. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double blind studies. JAMA, 275: 1507–1513 (1996).PubMedCrossRefGoogle Scholar
  13. 13.
    Dahlöf B, Hansson L: The influence of antihypertensive therapy on the structural vascular amplifying mechanism in essential hypertension. Different effects of Enalapril and Hydrochlorothiazide. J Hypertens, 10: 1513–1524 (1992).PubMedCrossRefGoogle Scholar
  14. 14.
    Schulman S, Weiss J Becker L et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. New Eng J Med, 322,19: 1350–1356 (1990).PubMedCrossRefGoogle Scholar
  15. 15.
    Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Emler P, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR, on behalf of Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA, 270: 713–724 (1993).PubMedCrossRefGoogle Scholar
  16. 16.
    Agabiti-Rosei E, Ambrosioni E, DalPalu’ C, Muiesan ML, Zanchetti A on behalf of the RACE Study group. Ace-inhibitor ramipril is more effective than β-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens, 13: 1325–1335 (1995).PubMedCrossRefGoogle Scholar
  17. 17.
    Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study group on antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension Comparison of six antihypertensive agents. The Departement of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation, 95: 2007–2014 (1997).PubMedCrossRefGoogle Scholar
  18. 18.
    Trimarco B, De Luca N, Ricciardelli B, Rosiello G, Volpe M, Condorelli G, Lembo G, Condorelli M. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol, 62: 745–750 (1988).PubMedCrossRefGoogle Scholar
  19. 19.
    Schmieder RE, Messerli FH, Sturgill D, Garavaglia GE, Nunez BD. Cardiac performance after reduction of myocardial hypertrophy. Am J Med, 87: 22–27 (1989).PubMedCrossRefGoogle Scholar
  20. 20.
    Muiesan ML, Agabiti-Rosei E, Romanelli G, et al. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal and revedelopment of hypertension. J. Cardiovasc. Pharmacol, 17: 179s–181s (1991).CrossRefGoogle Scholar
  21. 21.
    Agabiti Rosei E. Romanelli G, Muiesan ML et al. Impaired response of the hypertrophied left ventricle to beta adrenergic stimulation in hypertensive patients. Circulation, 70(Suppl. II): 61 (1984).Google Scholar
  22. 22.
    Grassi G, Gianattasio C, Cleroux J, Cuspidi C, Sampieri L, Mancia G. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension, 12: 227–231 (1988).PubMedCrossRefGoogle Scholar
  23. 23.
    Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frolich ED. Hypertension and sudden death: disparate effects of calcium entry blocker and diuretic therapy on cardiac disrrhythmias. Arch. Intern. Med, 149: 1263–1267 (1989).PubMedCrossRefGoogle Scholar
  24. 24.
    Muiesan ML Rizzoni D, Rulli R, Calebich S, Malerba M, Porteri E, Agabiti-Rosei E. Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension. J Hypertens, 11(suppl 5): s300–301 (1993).Google Scholar
  25. 25.
    Magrini F, Reggiani P, Roberts N, Meazza R, Ciulla M, Zanchetti A. Effects of angiotensin blockade on coronary circulation and coronary reserve. Am J Med, 84: 55–60 (1988).PubMedCrossRefGoogle Scholar
  26. 26.
    Levy D, Salomon M, D’Agostino R, Belanger A, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 90:1786–93 (1994).PubMedCrossRefGoogle Scholar
  27. 27.
    Koren MJ, Savage DD, Casale PN, Laragh JH, Devereux RB. Changes in left ventricular mass predict risk in essential hypertension. Circulation, 82(suppl III): III29 (Abstract) (1990).Google Scholar
  28. 28.
    Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy multicenter trial Am J Hypertens, 5 (suppl): 182s–189s (1992).PubMedGoogle Scholar
  29. 29.
    Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in LV mass with prognosis during long-term antihypertensive treatment. J Hypertens 13: 1091–1105 (1995).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  1. 1.Cattedra Semeiotica e Metodologia MedicaUniversita’ di BresciaItaly

Personalised recommendations